×
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
NASDAQ:TRVN

Trevena Stock Forecast, Price & News

$0.39
-0.02 (-4.88%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.38
$0.42
50-Day Range
$0.20
$0.46
52-Week Range
$0.18
$1.72
Volume
1.25 million shs
Average Volume
1.51 million shs
Market Capitalization
$64.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75

Trevena Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1,117.9% Upside
$4.75 Price Target
Short Interest
Healthy
11.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.41mentions of Trevena in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$13.03 K Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.37) to ($0.34) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.67 out of 5 stars

Medical Sector

660th out of 1,429 stocks

Pharmaceutical Preparations Industry

311th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive TRVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

Trevena logo

About Trevena (NASDAQ:TRVN)

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

TRVN Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TRVN
Fax
N/A
Employees
25
Year Founded
N/A

Company Calendar

Last Earnings
5/11/2022
Today
7/01/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$4.75
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$3.50
Forecasted Upside/Downside
+1,117.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.5
Research Coverage
2 Analysts

Profitability

Net Income
$-51.59 million
Net Margins
-7,771.74%
Pretax Margin
-15,379.63%

Debt

Sales & Book Value

Annual Sales
$570 thousand
Book Value
$0.39 per share

Miscellaneous

Free Float
159,561,000
Market Cap
$64.55 million
Optionable
Optionable
Beta
2.44














Trevena Frequently Asked Questions

Should I buy or sell Trevena stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Trevena stock.
View analyst ratings for Trevena
or view top-rated stocks.

What is Trevena's stock price forecast for 2022?

2 brokerages have issued 1 year price targets for Trevena's shares. Their TRVN stock forecasts range from $3.50 to $6.00. On average, they predict Trevena's stock price to reach $4.75 in the next twelve months. This suggests a possible upside of 1,117.9% from the stock's current price.
View analysts' price targets for Trevena
or view top-rated stocks among Wall Street analysts.

How has Trevena's stock performed in 2022?

Trevena's stock was trading at $0.5830 at the beginning of 2022. Since then, TRVN stock has decreased by 33.1% and is now trading at $0.39.
View the best growth stocks for 2022 here
.

When is Trevena's next earnings date?

Trevena is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Trevena
.

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) posted its quarterly earnings data on Wednesday, May, 11th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.65 million. Trevena had a negative trailing twelve-month return on equity of 82.39% and a negative net margin of 7,771.74%. During the same period in the previous year, the firm posted ($0.06) earnings per share.
View Trevena's earnings history
.

Who are Trevena's key executives?

Trevena's management team includes the following people:
  • Ms. Carrie L. Bourdow, Pres, CEO & Director (Age 59, Pay $920.39k) (LinkedIn Profile)
  • Mr. Barry Shin, Sr. VP & CFO (Age 50, Pay $609.94k)
  • Dr. Mark A. Demitrack, Sr. VP & Chief Medical Officer (Age 64, Pay $641.3k)
  • Dr. Howard A. Rockman M.D., Scientific Founder, Consultant and Member of Scientific Advisory Board
  • Mr. Joel Solomon, VP, Head of Legal, Chief Compliance Officer & Corp. Sec.
  • Mr. Michael Catalano, VP of Marketing
  • Mr. Robert T. Yoder, Sr. VP, Chief Bus. Officer & Head of Commercial Operations (Age 56)
  • Ms. Patricia M. Drake, Sr. VP & Chief Commercial Officer (Age 56)

What other stocks do shareholders of Trevena own?

What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

How do I buy shares of Trevena?

Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevena's stock price today?

One share of TRVN stock can currently be purchased for approximately $0.39.

How much money does Trevena make?

Trevena (NASDAQ:TRVN) has a market capitalization of $64.55 million and generates $570 thousand in revenue each year. The biopharmaceutical company earns $-51.59 million in net income (profit) each year or ($0.35) on an earnings per share basis.

How many employees does Trevena have?

Trevena employs 25 workers across the globe.

How can I contact Trevena?

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The official website for Trevena is www.trevena.com. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at [email protected].

This page (NASDAQ:TRVN) was last updated on 7/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.